SCHEMBL684364

SCHEMBL684364

Cn1c(=O)c2c(ncn2CN2CCN(C(c3ccccc3)c3ccccc3)CC2)n(C)c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.66
CHRM1 P11229 3/20 0.66
DRD2 P14416 3/20 0.66
ADRA1D P25100 3/20 0.66
ADRA1A P35348 3/20 0.66
ADRA1B P35368 3/20 0.66
HTR2A P28223 3/20 0.61
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
MAPK1 P28482 1/20 0.56
RXFP1 Q9HBX9 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ADORA2B P29275 1/20 0.56
HTR7 P34969 1/20 0.55
HTR6 P50406 1/20 0.55
ALDH1A1 P00352 1/20 0.55
POLB P06746 1/20 0.54
TSHR P16473 1/20 0.53
CHRM2 P08172 1/20 0.52
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684054 0.94 HTR1A (0.62) HTR1ACHRM1DRD2ADRA1DADRA1A
Hydrochloric Acid SCHEMBL2796668 0.86 HTR1A (0.61) HTR1ACHRM1DRD2ADRA1DADRA1A
SCHEMBL683655 0.83 HTR7 (0.77) HTR1AHTR2AKMT2AMEN1MAPK1
SCHEMBL684006 0.83 CHRM2 (0.72) HTR1ACHRM1DRD2ADRA1DADRA1A
SCHEMBL684071 0.82 HTR2A (0.81) HTR1ACHRM1DRD2ADRA1DADRA1A
SCHEMBL7742121 0.80 ADORA2B (0.62) KMT2AMAPK1RXFP1SMN1; SMN2ADORA2B
SCHEMBL684015 0.79 LMNA (0.49) HTR1ACHRM1DRD2ADRA1DADRA1A
SCHEMBL10744377 0.79 ADRA1A (1.00) HTR1ACHRM1DRD2ADRA1DADRA1A
SCHEMBL683615 0.79 ADORA2B (0.57) HTR1ACHRM1DRD2ADRA1DADRA1A
SCHEMBL7736301 0.79 ADORA2B (0.60) KMT2AMAPK1RXFP1SMN1; SMN2ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR1A 1265/4885CHRM1 1036/4885DRD2 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.